An in vitro antiviral activity of iodine complexes against SARS-CoV-2

Altaf, Imran; Nadeem, Muhammad Faisal; Hussain, Nadir; Nawaz, Muhammad; Raza, Sohail; Shabbir, Muhammad Abu bakr; Ashraf, Muhammad Adnan; Ali, Muhammad Asad; Hassan, Sohail; Aziz, Muhammad Waqar; Matti, Nazish; Ashraf, Muhammad; Ulla, Ihsan; Fazal, Sehar; Rafique, Saira; Mehmood, Adnan; Sardar, Nageen; Khan, Muhammad Tahir; Atique, Hafiz Muhammad Moavia; Ashraf, Sohaib; Tahir, Zarfishan; Mukhtar, Nadia; Yaqub, Tahir

Since the emergence of COVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule)of an Iodine-complex (Renessans). First, cell cytotoxicity of Renessans on the Vero cells was determined using MTT assay. Afterwards, the antiviral activity of Renessans was determined using viral inhibition assays and TCID(50). For this, nontoxic concentrations of the Renessans were used. The results showed that Renessans is nontoxic to the cells up to 50 µg/mL. At 1.5 µg/mL concentration, SARS-CoV-2 production was significantly reduced to 10(1.43) TCID(50) and 10(1.58) TCID(50) for the syrup and capsule, respectively, as compare to virus infected control cells 10(6.08) TCID(50) and we found the dose dependent inhibition of virus replication in the presence of Renessans. Renessans inhibited SARS-CoV-2 with an EC50 value of 0.425 µg/mL and 0.505 µg/mL for syrup and capsule, respectively. Furthermore, there was no virus detected at concentration of 50 µg/mL of Renessans. This study indicates that Renessans, containing iodine, have potential activity against SARS-CoV-2 which needs to be further investigated in human clinical trials.